The journal of allergy and clinical immunology. Global

Exercise-related severe allergic reaction linked to medication that affects digestion hormones: A case report

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated

Abstract

A patient developed exercise-induced anaphylaxis after starting tirzepatide.

  • The anaphylactic reaction was triggered by exercise.
  • Symptoms resolved after discontinuation of tirzepatide.
  • This case highlights a potential adverse effect associated with tirzepatide.

Simplified

Full Text

Full text is available at the source.
View Full Text ↗

Funding

Competing interests

Disclosure of potential conflict of interest: The authors declare that they have no relevant conflicts of interest.
PubMed

Related papers

Nov '21
Tirzepatide, a new medicine that activates two blood sugar hormones, as a potential heart and metabolism treatment
top 2% journal
cited by 106 papers
journal article
Jun '25
Thyroid inflammation linked to tirzepatide, a drug acting on two blood sugar hormones: a case report
cited by 3 papers
case reports
Feb '24
A case of a whole-body allergic reaction to the diabetes drug tirzepatide
cited by 4 papers
case reports
Jun '20
Tirzepatide briefly slows stomach emptying like long-acting GLP-1 receptor drugs
top 5% journal
cited by 123 papers
research support, non-u.s. gov't
Jan '22
Effectiveness and safety of high-dose hormone treatments targeting blood sugar control in type 2 diabetes
cited by 26 papers
journal article
Oct '20
Tirzepatide: a new drug that activates two hormones to help treat type 2 diabetes
cited by 60 papers
research support, non-u.s. gov't
Aug '23
How activating the glucose-dependent insulinotropic polypeptide receptor may influence tirzepatide’s effects
top 5% journal
cited by 32 papers
journal article
Dec '20
Tirzepatide, a medicine targeting two hormones, in managing Type 2 diabetes: Results from the SURPASS trials
top 20% journal
cited by 243 papers
journal article

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free

Recent issues from the glp-1 therapies brief

issue #48
Stop the drug, regain the weight: pooled data puts the average rebound at 7%
2 days ago7 studies
issue #47
The brain region that explains why blocking and activating the same receptor both cause weight loss
1 week ago7 studies
issue #46
GLP-1 drugs linked to lower depression and bipolar disorder risk in large genetic study
2 weeks ago7 studies
issue #45
Stopping GLP-1 drugs linked to higher depression and anxiety risk in type 2 diabetes patients
3 weeks ago7 studies
issue #44
Tirzepatide cut all-cause mortality by more than half compared to semaglutide in a 47,000-patient study
4 weeks ago7 studies
issue #43
Semaglutide linked to 21% lower psychiatric hospitalization risk in bipolar disorder patients
5 weeks ago7 studies
issue #42
Tirzepatide users lost 14.7% of body weight vs. 10.8% with semaglutide — but Black and Hispanic patients were overrepresented in the lowest-response group
6 weeks ago8 studies
issue #41
New obesity drug survodutide cut weight by 13% vs 5.4% for placebo in 725 patients
7 weeks ago7 studies
issue #40
GLP-1 users had 3x higher risk of aspiration pneumonia after stroke surgery
8 weeks ago7 studies
issue #39
Semaglutide linked to reduced cigarette craving in 24 smokers
9 weeks ago7 studies
explore the archive
See more issues from the glp-1 therapies brief